
Home » DiscGenics Grabs FDA Fast Track Designation for Cell Therapy
DiscGenics Grabs FDA Fast Track Designation for Cell Therapy
The FDA granted fast track status for DiscGenics’ cell therapy for degenerative disc disease.
The non-invasive treatment, IDCT, is currently being evaluated in two multicenter trials in the U.S. and Japan for treating patients with mild to moderate lumbar DDD. The condition, which isn’t actually a disease, involves pain from one or more deteriorated intervertebral discs that can range from annoying to debilitating.
The company in January announced its U.S. study of the drug-biologic showed safety in the first cohort of patients, with no issues arising from first-time administration.
Upcoming Events
-
28Sep
-
28Sep
-
11Oct
-
16Oct
-
26Oct
-
08Nov